For localized information and support, would you like to switch to your country-specific website for {0}?
Key takeaways
Heart failure in people living with diabetes often presents as heart failure with preserved ejection fraction (HFpEF), with this phenotype being driven by complex cardio-renal-metabolic pathophysiology
Proactive screening utilizing NT-proBNP testing (N-terminal pro-B-type natriuretic peptide) and echocardiography can uncover a high burden of unrecognized symptomatic heart failure in diabetes, achieving diagnosis with a remarkably low number of patients needed to screen
Early implementation of disease-modifying pharmacotherapies prior to symptom onset could significantly improve cardiovascular event-free survival and overall life expectancy
The diagnostic need of early heart failure recognition in people with diabetes
Heart failure (HF) is highly prevalent in people with diabetes, and may be one of the first cardiovascular complications, developing early and progressing silently.1,2 Despite this prevalence, diagnosis is frequently delayed, due to the fact that symptoms can be misattributed to common diabetic comorbidities such as obesity, generalized deconditioning, or aging.2,3 As a result, the initiation of life-saving, disease-modifying therapies is often delayed, an issue that could be solved through a shift from reactive symptom management to proactive diagnostic screening for the benefit of the patient. Two renowned experts outline clinical rationale, trial data, and pathophysiological basis for early HF identification and prompt pharmacotherapy initiation in patients with diabetes.
Early heart failure detection in diabetes: TARTAN-HF
Dr. Docherty reviews TARTAN-HF data, showing that proactive NT-proBNP testing in patients with diabetes can detect unrecognized HFpEF and accelerate the initiation of disease-modifying therapies.
In his presentation, Dr. Kieran Docherty draws attention to the European Society of Cardiology ESC diabetes guidelines, which recommend a systematic survey for HF symptoms and signs at every clinical encounter for all diabetic patients. If symptoms, physical signs, or electrocardiographic abnormalities are present, clinicians should measure NT-proBNP levels. Elevated natriuretic peptide levels should then subsequently prompt a formal echocardiographic assessment.1
Meanwhile the American Diabetes Association (ADA) diabetes and heart failure guidelines advocate an even more proactive framework: measuring natriuretic peptides on a yearly basis for asymptomatic patients.2 The objective is the identification of preclinical, stage B heart failure, indicating progression toward overt symptomatic disease that can be addressed by early use of preventative therapies.
Dr. Docherty shares that real-world data further underscore the inadequacy of current diagnostic pathways. Epidemiological data from the United Kingdom illustrate that approximately 80% of patients with a first documented heart failure diagnosis receive this diagnosis during an acute hospital admission.3 A review of primary care records in this study revealed that 41% of these individuals had documented HF symptoms in the preceding five years.3 Importantly, 44% out of individuals with symptoms did not receive appropriate diagnostic evaluation with natriuretic peptide measurement or echocardiography.3
TARTAN-HF trial: Evaluating natriuretic peptide–based heart failure screening
Dr. Docherty presented recent data from the targeted assessment in high-risk patients with diabetes to identify undiagnosed heart failure (TARTAN-HF) trial. This prospective, randomized trial evaluated the diagnostic yield of a natriuretic peptide-based screening strategy in individuals with diabetes and at least one additional heart failure risk factor.4 Excluding patients with established disease, participants were randomized to proactive screening or standard care. In the screening arm, an NT-proBNP level ≥125 pg/mL prompted diagnostic echocardiography. The primary endpoint assessed the incidence of new HF diagnoses confirmed within six months of randomization.4
The trial demonstrated substantial diagnostic efficacy. In the screening cohort of 374 patients, nearly 50% exhibited elevated NT-proBNP levels. Following echocardiography, 25% of patients received a new diagnosis of unrecognized symptomatic heart failure. In contrast, routine clinical care identified only two cases of heart failure over the same six-month period.4
The proactive HF screening catalyzed significant changes in medical management. Most notably, the diagnosis prompted a marked increase in the prescription of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Baseline use of these preventative therapies was low, with only 21% of patients receiving an SGLT2 inhibitor prior to screening.4
Exploratory outcome analyses provided evidence for the clinical value of this screening strategy. Patients randomized to the proactive screening arm experienced a 55% reduction in the composite risk of HF hospitalization or all-cause mortality compared to the usual care arm.4 While event numbers were small at this preliminary stage, long-term follow-up spanning ten years is planned.
The TARTAN-HF data presented by Dr. Docherty presents evidence that targeted NT-proBNP screening detects a high volume of unrecognized HF, largely HFpEF, facilitates the rapid implementation of disease-modifying therapies, and has the potential to alter clinical trajectories.4
Cardio-kidney-metabolic pathophysiology and prevention: Insights from Prof. Cristina Gavina
Prof. Gavina explores the cardio-renal-metabolic continuum, explaining how early multi-pillar pharmacotherapy prevents silent heart failure progression and improves survival in diabetes.
Providing support for Dr. Docherty’s emphasis on early detection, Professor Cristina Gavina highlights the importance of proactive intervention across the cardio-kidney-metabolic (CKM) continuum, since diabetes rarely exists in isolation. Approximately one-third of diabetic patients develop cardiovascular disease (frequently presenting as heart failure),5 while 20-40% of heart failure cohorts have comorbid diabetes.6 The co-occurrence of chronic kidney disease further compounds this clinical risk.7,8
Within this interconnected continuum, myocardial remodeling and diastolic dysfunction can advance silently despite adequate glycemic control, predisposing patients to acute decompensation, as in the patient case presented by Prof. Gavina. Such silent progression can carry a severe prognostic outcome: registry data in over 150,000 Danish diabetic individuals demonstrate that incident heart failure reduces life expectancy by a full year over a five-year period.9
Prof. Gavina clarifies that since glycemic control and lifestyle modifications alone cannot arrest a multi-organ trajectory, effective prevention demands the early initiation of organ-protective pharmacotherapies, such as SGLT2 inhibitors, alongside the discontinuation of medications associated with increased heart failure risk.
Pathophysiology of the CKM syndrome
The pathophysiology of the CKM syndrome centers on dysfunctional adipose tissue, which can act as an active endocrine organ secreting a number of cytokines and hormones that are toxic to several organs.10 This endocrine activity drives systemic inflammation, which further induces microvascular dysfunction, oxidative stress, and subsequent tissue fibrosis.10,11 In the myocardium, these processes cause cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction; in the kidney, identical inflammatory mechanisms drive glomerulosclerosis and interstitial fibrosis; liver parenchyma is also subjected to similar metabolic damage. This systemic fibrotic and inflammatory state represents one unified pathway of multi-organ injury.11
The American Heart Association (AHA) codifies this progression through the stages of the cardio-kidney-metabolic continuum. Stage 0 represents no risk factors. Stage 1 includes baseline risk factors like obesity. Stage 2 involves metabolic disease and CKD. Stage 3 defines subclinical disease, such as structural heart changes without symptoms (Stage B heart failure), and in Stage 4 there is overt disease.11
Multi-pillar pharmacotherapy and survival benefits
Prof. Gavina highlights that addressing a disease of this complexity requires combination therapy with clinicians needing to intervene early and aggressively. SGLT2 inhibitors provide robust cardiovascular protection and prevent progression to overt heart failure. Glucagon-like peptide-1 (GLP-1) receptor agonists effectively control HbA1c, reducing major adverse cardiovascular events, and inducing significant weight loss. Non-steroidal mineralocorticoid receptor antagonists (nsMRAs), such as finerenone, mitigate inflammation and fibrosis. Renin-angiotensin system (RAAS) inhibition remains a foundational therapeutic pillar.10
Clinical trial data confirm the efficacy of these interventions across different stages of disease and implementing a combination regimen comprising an SGLT2 inhibitor, a GLP-1 receptor agonist, a nsMRA, and RAAS blockade can yield transformative prognostic benefits.12 2024 data on combination therapy shows that initiating such therapy in a high-risk 50-year-old patient can provide quantifiable survival advantages.12 Patients gain an estimated two to three additional years free from major adverse cardiovascular events or heart failure hospitalizations, and five additional years of survival without CKD progression.12 Most importantly, early multi-pillar intervention provides five additional years of overall survival.12
Prof. Gavina emphasizes that clinicians must not wait for the onset of overt clinical symptoms. High-risk patients with cardio-kidney-metabolic disease require the immediate, proactive deployment of disease-modifying therapies to halt disease progression and extend life expectancy.
Conclusion
The insights provided by Dr. Docherty and Prof. Gavina demand a fundamental reconsideration of routine diabetic care. The two specialists both provide evidence that the traditional model of waiting for overt clinical symptoms to be recognized often results in delayed diagnoses, increased hospitalizations, and preventable mortality.3,9 Systematic screening with NT-proBNP can identify high-risk individuals and those with unrecognized HFpEF.4 Once identified, the pathophysiological drivers of the cardio-renal-metabolic syndrome should be eliminated through combinations therapy - the deployment of SGLT2 inhibitors, GLP-1 receptor agonists, and nsMRAs can provide highly effective, multi-organ protection.12 Integrating biomarker screening with proactive, early combination pharmacotherapy is essential to altering the progression of heart failure in diabetic populations.
References
Marx N, et al. ESC Scientific Document Group. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-40. Erratum in: Eur Heart J. 2023;44(48):5060. Erratum in: Eur Heart J. 2024;45(7):518.
American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care 2026; 49 (Supplement_1): S216–45.
Bottle A, et al. Routes to diagnosis of heart failure: observational study using linked data in England. Heart. 2018 104(7):600-5.
Taylor-Sweet D, et al. Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). J Am Coll Cardiol. 2026;88(15):1764-76.
Einarson TR, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
Thomas MC. Type 2 Diabetes and Heart Failure: Challenges and Solutions. Curr Cardiol Rev. 2016;12(3):249-55.
Afkarian M, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA. 2016;316(6):602-10.
Lovre D, et al. Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. Endocrinol Metab Clin North Am. 2018;47(1):237-57.
Zareini B, et al. Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. Circ Cardiovasc Qual Outcomes. 2020;13(7):e006260.
Sebastian SA,et al. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024;49(2):102344.
Ndumele CE, et al; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. Erratum in: Circulation. 2024;149(13):e1023.
Neuen BL, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-62.